The Library

Anti-colorectal cancer activity of an organometallic osmium arene azopyridine complex

Tools

Shnyder, Steve D., Fu, Y. (Ying), Habtemariam, Abraha, van Rijt, Sabine H., Cooper, Patricia A., Loadman, Paul M. and Sadler, P. J.. (2011) Anti-colorectal cancer activity of an organometallic osmium arene azopyridine complex. MedChemComm, Vol.2 (No.7). pp. 666-668. ISSN 2040-2503

Preview

Text
WRAP_Fu_467_MCC_2011_Ying Fu_2_666_deposit.pdf - Accepted Version
Download (450Kb) | Preview

Official URL: http://dx.doi.org/10.1039/c1md00075f

Abstract

This first in vivo antitumour activity for an organometallic osmium arene complex, [Os(eta(6)-p-cym)(4-(2-pyridylazo)-N,N-dimethylaniline)I]PF(6), is reported. The complex delays the growth of HCT116 human colon cancer xenografts in mice, with negligible toxicity. Its activity appears to involve redox mechanisms and its potency towards A2780 ovarian and A549 lung cancer cells is increased significantly in combination with L-buthionine-sulfoximine.

[error in script] [error in script]

Item Type:	Journal Article
Subjects:	Q Science > QD Chemistry R Medicine > RM Therapeutics. Pharmacology
Divisions:	Faculty of Science > Chemistry
Library of Congress Subject Headings (LCSH):	Organometallic compounds -- Physiological effect, Antineoplastic agents -- Research, Clinical pharmacology, Colon (Anatomy) -- Cancer -- Treatment -- Research, Rectum -- Cancer -- Treatment -- Research
Journal or Publication Title:	MedChemComm
Publisher:	Royal Society of Chemistry
ISSN:	2040-2503
Date:	July 2011
Volume:	Vol.2
Number:	No.7
Page Range:	pp. 666-668
Identification Number:	10.1039/c1md00075f
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
Funder:	Engineering and Physical Sciences Research Council (EPSRC), European Research Council (ERC), European Regional Development Fund (ERDF), Advantage West Midlands (AWM), European Union (EU)
Grant number:	247450 (ERC)
References:	(1) (a) Bioorganometallics: Biomolecules, Labeling, Medicine. Ed. G. Jaouen, Wiley_VCH Verlag GmbH & Co. KGaA: Weinheim, 2006.(b) Medicinal Organometallic Chemistry Series: Topics in Organometallic Chemistry, ed. Jaouen, Gérard and Metzler-Nolte, Nils , vol 32, 2010, Springer-Verlag, Berlin. (2) Peacock, A.F.A; Sadler, P.J. Chem. Asian J. 2008, 3, 1890-1899. (3) Aird, R. E.; Cummings, J.; Ritchie, A. A.; Muir, M.; Morris, R. E.; Chen, H.; Sadler, P. J.; Jodrell, D. I. Br. J. Cancer 2002, 86, 1652-1657. (4) Guichard, S. M.; Else, R.; Reid, E.; Zeitlin, B.; Aird, R.; Muir, M.; Dodds, M.; Fiebig, H.; Sadler, P. J.; Jodrell, D. I. Biochem. Pharmacol. 2006, 71, 408-415. (5)Novakova, O.; Chen, H.; Vrana, O.; Rodger, A.; Sadler, P. J.; Brabec, V. Biochemistry 2003, 42, 11544-11554. (6) Bergamo, A.; Masi, A.; Peacock, A. F. A.; Habtemariam, A.; Sadler, P. J.; Sava, G. J. Inorg. Biochem. 2009, 104, 79-86 (7) Dougan, S.J.; Habtemariam, A.; McHale, S. E.; Parsons, S.; Sadler, P. J.. Proc. Natl. Acad. Sci. USA 2008, 105, 11628-11633. (8) Fu, Y.; Habtemariam, A.; Pizarro, A. M.; van Rijt, S. H.; Healey, D. J.; Cooper, P. A.; Shnyder, S. D.; Clarkson, G. J.; Sadler, P. J. J. Med. Chem. 2010, 53, 8192-8196. (9) Dorr, R. T.; Liddil, J. D.; Soble, M. J. Invest. New Drugs 1986, 4, 305-313. (10) Peacock, A. F. A.; Habtermariam, A.; Moggach, S.; Prescimone, A.; Parsons S.; Sadler, P. J. Inorg. Chem. 2007, 44, 4049-4059. (11) Trachootham, D.; Alexandre, J.; Huang, P. Nat. Rev. Drug. Discov. 2009, 8, 579-591. (12) (a) Wang, H.; Joseph, J. A. Free Radical Biology and Medicine 1999, 1, 612-616. (b) Gomes, A.; Fernandes, E.; Lima, J. L. F. C. J. Biochem. Biophys. Methods 2005, 1, 45-80. (13) Halliwell, B.; Whiteman, M. Br. J. Pharmacol. 2004, 142, 231-255.
URI:	http://wrap.warwick.ac.uk/id/eprint/38704